title: Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.
abstract: OBJECTIVE
  To describe a case of Cushing syndrome in a child during concurrent use of inhaled fluticasone propionate, nasal mometasone, and a highly active antiretroviral regimen including lopinavir/ritonavir.
  
  
  METHODS
  A 9-year-old boy with HIV infection and asthma developed moon facies, increased facial hair, and increased weight after fluticasone propionate inhalation (1 puff; 220 microg) therapy was begun. His antiretroviral regimen contained the protease inhibitor combination lopinavir/ritonavir at a dose of 216/54 mg twice daily, and he had been stable for the previous 5 years. He had also been receiving intranasal mometasone for 11 months for the management of allergic rhinitis. Serum cortisol and adrenocorticotropic hormone levels were consistent with adrenal suppression. These physical findings and symptoms and laboratory values normalized after discontinuation of the fluticasone propionate. The Naranjo probability scale indicated that a probable interaction occurred between lopinavir/ritonavir and fluticasone propionate, leading to subsequent adrenal suppression.
  
  
  CONCLUSIONS
  Protease inhibitors are associated with numerous drug interactions due to inhibition of the CYP3A4 isoenzyme. Pharmaceutical agents used to treat comorbidities in HIV-infected individuals often can interact with protease inhibitors, leading to toxic drug concentrations or untoward effects. Inhaled corticosteroids such as fluticasone propionate are often necessary to treat asthma in young children and are metabolized by CYP3A4. Interactions between protease inhibitors and inhaled fluticasone propionate have been reported in the adult population, but reports are limited in the pediatric literature.
  
  
  CONCLUSIONS
  This case raises awareness of the interaction between fluticasone propionate and lopinavir/ritonavir and adverse effects in children receiving both medications.
authors.affiliation: Department of Pediatrics, College of Medicine, University of Toledo, Toledo, OH, USA.
authors.forename: Nasreen A
authors.initials: NA
authors.lastname: Bhumbra
authors.forename: Eric G
authors.initials: EG
authors.lastname: Sahloff
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Oehrtman
authors.forename: James M
authors.initials: JM
authors.lastname: Horner
mesh_terms: D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D003480:Cushing Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D004359:Drug Therapy, Combination; D000068298:Fluticasone; D006801:Humans; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000730:Androstadienes; D011744:Pyrimidinones; D061466:Lopinavir; D000068298:Fluticasone; D019438:Ritonavir